Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Earlier roles on record: CEO and Board Member at Travere Therapeutics, Inc. (TVTX) until December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed September 21, 2026 that Eric Dube resigned as member of the Board of Directors, effective December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed September 21, 2026 that Eric Dube resigned as President and Chief Executive Officer, effective December 1, 2026. Travere Therapeutics, Inc. reported in an 8-K filed May 16, 2025 that Eric Dube was appointed Director, effective May 15, 2025. Equibles holds 5 filed executive changes naming Eric Dube; each is listed under recent activity with its source filing. The proxy statement of Travere Therapeutics, Inc. reports total compensation of $8,457,151 for Eric Dube in fiscal 2025, including a base salary of $854,250. Disclosed compensation is on record for 7 fiscal years. Eric Dube has spoken on 26 earnings calls and 3 other investor events across 1 company, most recently for Travere Therapeutics, Inc. on August 4, 2026.
“who will step down from his position as the Company's President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026”
“Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company's President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2019-01-01–2026-12-01
Start not stated–2026-12-01
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2019-01-01–2026-12-01
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $854,250 | $8,457,151 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $822,000 | $5,204,877 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $795,834 | $7,574,959 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $746,667 | $5,753,490 |
| 2021 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $708,021 | $5,739,010 |
| 2020 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $660,938 | $5,447,879 |
| 2019 | Travere Therapeutics, Inc. (TVTX) | President, Chief Executive Officer and Director | $618,188 | $9,679,319 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
